Vicki Sato is listed as a director on 16 SEC Form D filings by 6 issuers between May 2009 and May 2020. Largest by amount reported sold: Vir Biotechnology, Inc. (San Francisco, CA — biotechnology — 2018–2020; $250M reported sold to 5 investors), Syros Pharmaceuticals, Inc. (Cambridge, MA — biotechnology — 2014–2018; $129.8M reported sold to 19 investors), Akouos, Inc. (Boston, MA — biotechnology — 2020; $105.1M reported sold to 33 investors), PROCLARA BIOSCIENCES, INC. (Cambridge, MA — biotechnology — 2011–2014; $43M reported sold to 54 investors), AVILA THERAPEUTICS INC (Waltham, MA — biotechnology — 2009–2010; $22.5M reported sold to 9 investors) and 1 more (all listed below).
What this means A repeat sponsor — 6 separate companies raised money with this person listed as director, over about 11 years. Across those companies the filings report $553.9M sold in total.
Listed alongside Robert Nelsen (6 shared filings), Amir Nashat (5 shared filings), Bruce Booth (4 shared filings), Hampus Hillerstrom (4 shared filings), Jonathan Solomon (4 shared filings) and 54 others.
What this means These are the other officers, directors or promoters the companies named on the same forms — the team around Vicki. Each name links to their own page.
Public records searched: federal courts (CourtListener / RECAP), SEC enforcement releases, state securities regulators (AZ, CA, DE, TX, WA) — none found.
What this means Nothing turned up where we looked (3 sources). That does not prove there is nothing — it means none was found in those sources on that date.
We compared 16 public filings for Vicki Sato and found 12 differences: Form D filed 18 days after the first sale; Form D filed 19 days after the first sale; and more below.
What this means These are differences between the sponsor's own SEC filings — both values, dates and sources are listed in Key records, section 4. Most have ordinary explanations; ask the sponsor.